TLimmuno2 produces stable predictions and outperforms existing methods. (A) The ROC curves of TLimmuno2 on 5-fold cross-validation. (B) The ROC curves of TLimmuno2 on training process. (C) The ROC curve of TLimmuno2, IEDB (CD4episcore), Repitope, NetMHCIIpan BA and EL in the testing set. (D) The ROC curve of TLimmuno2, IEDB (CD4episcore), Repitope, NetMHCIIpan BA and EL in the neoepitope dataset by using the 15-mer method. (E) The ROC curve of TLimmuno2, NetMHCIIpan BA and EL in the neoepitope dataset by using the k-mer method.